Search clinical trials for: REGN6569

Total 72 results

Regeneron Pharmaceuticals

Terminated

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

Pain | Osteoarthritis of the Knee

United States, Georgia, Moldova, Republic of, Poland, Ukraine
Regeneron Pharmaceuticals

Completed

Safety, Tolerability, and Pharmacokinetics of REGN5069 in Healthy Volunteers

Healthy Volunteer

Belgium
Regeneron Pharmaceuticals
Sanofi

Completed

Ascending Dose Study of the Safety and Tolerability of REGN668(SAR231893) in Normal Healthy Volunteers

Healthy

United States
Regeneron Pharmaceuticals

Recruiting

Study of REGN6569 and Cemiplimab in Adult Patients With Advanced Solid Tumor Malignancies

Squamous Cell Carcinoma of Head and Neck

United States, Spain
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study of Patients Receiving DUPIXENT® for Atopic Dermatitis (AD) (PROSE)

Dermatitis, Atopic

United States, Canada
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Determine the Safety and Tolerability of Dupilumab (REGN668/SAR231893) in Patients Aged ≥6 to <18 Years With Atopic Dermatitis (Eczema)

Atopic Dermatitis

Germany, Poland, United Kingdom, Hungary, Canada, Czechia
Regeneron Pharmaceuticals

Available

Compassionate Use of Dupilumab

Bullous Pemphigoid | Pediatric Asthma | Pediatric Eosinophilic Esophagitis (EoE) | Pediatric and Adolescent Chronic Rhinosinusitis With Nasal Polyps (CRSwNP)
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Assess the Long-term Safety of Dupilumab Administered in Participants ≥6 Months to <18 Years of Age With Atopic Dermatitis (AD)

Atopic Dermatitis

United States, Canada, Czechia, Germany, Hungary, Poland, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab in Adult Patients With Extrinsic Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

Poland, Germany, France, Hungary, Czechia
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab Administered to Adult Patients With Moderate-to-Severe Atopic Dermatitis

Atopic Dermatitis

United States, Germany, Poland, Japan, Canada, Hungary, Czechia
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Confirm the Efficacy and Safety of Different Dupilumab Dose Regimens in Adults With Atopic Dermatitis (AD) (SOLO-CONTINUE)

Atopic Dermatitis
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Study to Investigate the Efficacy and Safety of Dupilumab in Pediatric Patients With Active Eosinophilic Esophagitis (EoE) (EoE KIDS)

Eosinophilic Esophagitis (EoE)

United States, Canada
Sanofi

Recruiting

A Study to Observe How Adolescent Patients With Severe Atopic Dermatitis Despite Less Extensive Skin Lesions (Eczema Area and Severity Index Score < 16) Respond to Dupilumab Treatment (AD-BEASCUITS)

Dermatitis Atopic

Italy
Regeneron Pharmaceuticals
Sanofi

Recruiting

Post-authorization Safety Study in North America to Monitor Pregnancy and Infant Outcomes Following Administration of Dupilumab During Planned or Unexpected Pregnancy

Asthma | Atopic Dermatitis (AD)

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Investigating Treatment With Dupilumab in Patients With Allergic Bronchopulmonary Aspergillosis (ABPA) (LIBERTY ABPA AIRED)

Allergic Bronchopulmonary Aspergillosis

United States, Hungary, Bulgaria, France, Germany, Japan, Netherlands, Poland, Romania, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Open-label Study of Dupilumab in Patients With Atopic Dermatitis

Atopic Dermatitis

Hungary, Netherlands, Spain, United Kingdom, United States, Australia, Austria, Belgium, Bulgaria, Canada, China, Czechia, Denmark, Estonia, Finland, France, Germany, Ireland, Italy, Japan, Korea, Republic of, Lithuania, New Zealand, ... and more
Regeneron Pharmaceuticals
Sanofi

Available

Compassionate Use of Dupilumab for Adult Patients With Bullous Pemphigoid

Bullous Pemphigoid
Regeneron Pharmaceuticals
Sanofi

Completed

Observational Study of Conjunctivitis in the Setting of DUPIXENT® Treatment for Atopic Dermatitis

Conjunctivitis | Atopic Dermatitis

United States
Sanofi

Recruiting

A Non-interventional Study to Describe the Dupilumab Long-term Treatment, Safety and Patient Reported Outcomes in Chronic Nodular Prurigo (Prurigo Nodularis) in Clinical Routine (CLEAR PN)

Prurigo Nodularis

Germany
Regeneron Pharmaceuticals
Sanofi

Recruiting

Study Assessing Long-teRm Outcomes of dupiluMAb (DUPIXENT®) Treatment in Adult Patients With Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP) (AROMA)

Chronic Rhinosinusitis With Nasal Polyposis

United States, Italy, Canada, Japan, Germany, Netherlands
Regeneron Pharmaceuticals
Sanofi

Recruiting

An Observational Retrospective Cohort Study Being Conducted in Women With Atopic Dermatitis (AD)

Atopic Dermatitis | Adverse Pregnancy Outcomes

United States
Regeneron Pharmaceuticals
Sanofi

Active, not recruiting

Registry of Asthma Patients Initiating DUPIXENT® (RAPID)

Asthma

United States, United Kingdom, Canada, France, Puerto Rico, Japan, Spain, Denmark, Italy, Sweden
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Evaluate Dupilumab Monotherapy in Pediatric Patients With Peanut Allergy

Peanut Allergy

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Comparison of the Pharmacokinetics and Safety of Two SAR231893 (REGN668) Drug Products in Healthy Subjects

Healthy

United States
Sanofi
Regeneron Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics (PK), Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants.

Healthy Volunteers

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of REGN668 Administered Subcutaneously to Healthy Volunteers

Healthy

United States
Sanofi
Regeneron Pharmaceuticals

Recruiting

A Study of Long-term Effect of Dupilumab on Skin Barrier Function in Pediatric Participants With Atopic Dermatitis (PELISTAD-EX2)

Dermatitis Atopic

United States, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab in Japanese Patients With Chronic Rhinosinusitis With Nasal Polyp (SINUS-M52)

Chronic Rhinosinusitis With Nasal Polyps

Japan
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab and Immune Responses in Adults With Atopic Dermatitis (AD)

Atopic Dermatitis

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Safety, Tolerability and Pharmacokinetics of SAR231893 (REGN668) in Healthy Japanese Adult Male Subjects

Healthy

Japan
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab-PEdiatric Skin Barrier Function and LIpidomics STudy in Patients With Atopic Dermatitis (PELISTAD)

Dermatitis Atopic

United States, United Kingdom
Sanofi
Regeneron Pharmaceuticals

Completed

Single Dose Comparability Study of New and Current Dupilumab Drug Products Subcutaneously Administered in Healthy Adults

Healthy Volunteers

United States
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab Effect on Pruritus Neuro-mechanisms in Patients With Atopic Dermatitis (DIFFEREN-STAD)

Dermatitis Atopic

United States, Germany
Sanofi
Regeneron Pharmaceuticals

Completed

Dupilumab Skin Barrier Function Study in Atopic Dermatitis (BALISTAD)

Atopic Dermatitis

United States, Canada
Sanofi
Regeneron Pharmaceuticals

Completed

Long-Term Safety Evaluation of Dupilumab in Patients With Asthma (LIBERTY ASTHMA TRAVERSE)

Asthma

Spain, Canada, Denmark, Belgium, Japan, Korea, Republic of, Mexico, United States, Israel, Brazil, Australia, France, Germany, United Kingdom, Argentina, Chile, Colombia, Hungary, Italy, Netherlands, Poland, Romania, Russian Federation and more
Regeneron Pharmaceuticals

Terminated

Study of REGN4659 in Combination With Cemiplimab in Patients With Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)

Carcinoma, Non-Small-Cell Lung

United States
Sanofi
Regeneron Pharmaceuticals

Active, not recruiting

Observational Study of Patients Receiving Dupixent® for Atopic Dermatitis (AD) (GLOBOSTAD)

Dermatitis Atopic

Spain, Czechia, Italy, Israel, Argentina, Australia, Austria, Belgium, Colombia, Finland, France, Greece, Japan, Kuwait, Mexico, Netherlands, Norway, Portugal, Russian Federation, Saudi Arabia, Taiwan, United Arab Emirates
Regeneron Pharmaceuticals

Recruiting

Short-Term Linvoseltamab Treatment, on Top of Chronic Dupilumab Treatment, for Adults With Severe Immunoglobulin E (IgE)-Mediated Food Allergy

Food Allergy

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Determine the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis

United States, Australia, Belgium, Canada, France, Germany, Italy, Netherlands, Spain, Sweden, Switzerland, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

A Study to Evaluate the Efficacy and Safety of Dupilumab in Adult and Adolescent Patients With Moderate-to-Severe Atopic Hand and Foot Dermatitis (Liberty-AD-HAFT)

Moderate to Severe Atopic Hand and Foot Dermatitis

United States, Germany, Japan, Poland
Sanofi
Regeneron Pharmaceuticals

Completed

Continuation of TRAVERSE- LTS12551 Evaluating Dupilumab Safety in Patients With Asthma (Long-Term Follow-Up)

Asthma

United States, Argentina, Belgium, Canada, France, Germany, Israel, Japan, Netherlands, South Africa
Regeneron Pharmaceuticals
Sanofi

Completed

Study of Dupilumab in Adult Participants With Active Eosinophilic Esophagitis (EoE)

Eosinophilic Esophagitis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Sequential Ascending Dose Study to Assess the Safety and Tolerability of REGN668 (SAR231893) in Patients With Atopic Dermatitis

Dermatitis

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL) (Liberty AD)

Dermatitis, Atopic

United States, Germany, Poland, United Kingdom
Regeneron Pharmaceuticals
Sanofi

Completed

Safety and Tolerability of Dupilumab in Participants With Moderate to Severe Atopic Dermatitis

Atopic Dermatitis

Germany, New Zealand, Australia
SagaNatura
Universidad Politecnica de Madrid

Unknown

NOGO for an Overactive Bladder (NOGO-OAB)

Overactive Bladder | Nocturia

Spain
Regeneron Pharmaceuticals
Sanofi

Completed

Efficacy and Safety of Dupilumab in Participants ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Hypersensitivity, Immediate | Dermatitis, Atopic | Moderate-to-Severe Atopic Dermatitis | Dermatitis, Dermatitis Atopic | Eczema, Skin Diseases, Skin | Diseases Genetic, Genetic | Diseases Inborn, Skin | Disease, Eczematous Skin | Hypersensitivity, Immune System Diseases

United States, Canada
Regeneron Pharmaceuticals

Recruiting

A Trial to Find Out How Safe REGN5668 is and How Well it Works When Given With Either Cemiplimab or REGN4018

Ovarian Cancer | Fallopian Tube Cancer | Endometrial Cancer | Primary Peritoneal Cancer

United States, Belgium
Sanofi
Regeneron Pharmaceuticals

Completed

A Study to Investigate the Pharmacokinetics, Tolerability and Safety of Two Different Dupilumab Drug Products in Healthy Participants

Healthy Volunteer

United States
Regeneron Pharmaceuticals
Sanofi

Completed

Study to Determine the Safety and Effectiveness of Dupilumab for Treatment of Atopic Dermatitis (AD)

Atopic Dermatitis (AD)

United States, Canada

Search clinical trials for: REGN6569

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Benin

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations